FDA Okays Pasireotide (Signifor LAR) for AcromegalyFDA Okays Pasireotide (Signifor LAR) for Acromegaly

The long-acting somatostatin analog pasireotide has been approved for the additional indication of treatment of acromegaly in the US, for patients who don't respond well to surgery or first-line agents. FDA Approvals
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news